Detalhe da pesquisa
1.
Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration.
Value Health
; 26(10): 1461-1473, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414276
2.
Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.
Value Health
; 24(7): 983-994, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34243842
3.
Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation.
Value Health
; 24(8): 1126-1136, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34372978
4.
Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
Radiology
; 297(1): 40-48, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749212
5.
Estimating Future Health Technology Diffusion Using Expert Beliefs Calibrated to an Established Diffusion Model.
Value Health
; 21(8): 944-950, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30098672
6.
When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices.
Value Health
; 19(6): 720-726, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27712696
7.
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework.
Drug Discov Today
; 29(6): 104008, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692506
8.
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.
Pharmacoeconomics
; 41(6): 619-632, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36943674
9.
Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 41(3): 239-251, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725788
10.
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 40(5): 509-518, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664200
11.
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments.
Pharmacoeconomics
; 39(10): 1185-1196, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34278550
12.
Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases").
Orphanet J Rare Dis
; 16(1): 62, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33522936
13.
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 39(12): 1397-1410, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34448148
14.
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 39(2): 171-180, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145711
15.
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.
Pharmacoeconomics
; 38(2): 205-216, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31709496
16.
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 38(4): 317-324, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31814080
17.
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 37(10): 1195-1207, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30895564
18.
Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 37(5): 655-667, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293207
19.
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.
Pharmacoeconomics
; 42(6): 615-618, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713424
20.
Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.
Pharmacoeconomics
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38717708